UNSPSC 51371505: Lefetamine

This classification denotes an analgesic agent with the molecular formula C16H19N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4J9726V5Y9, chemically known as 1-dimethylamino-1,2-diphenylethane but generally known as lefetamine, which bears US NIH Compound Identifier 22779. European Medicines Agency schedules Lefetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08423MIG.

UNSPSC 51371505 Lefetamine is a Commodity code under which state and local governments procure pharmaceutical products, though recent opportunities tagged to this code show a divergence between the code's nominal scope and actual purchasing activity. The code appears in practice to cover naloxone (an opioid-antagonist emergency medication), generic multi-source pharmaceuticals, and over-the-counter products distributed through state and local health systems, cooperative purchasing alliances, and county health departments. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work involves procurement of finished pharmaceutical products for inventory and distribution to public health facilities and employee health plans, with vendors typically required to supply through authorized wholesalers, maintain FDA compliance and current Good Manufacturing Practices certification, and meet specific insurance and supply-chain security standards.

Recent activity centers in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building, with bids due July 26, 2023 and E-Verify compliance required. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program under its Therapeutic Pharmacy Initiative, seeking information on direct contracting capacity outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026; this multi-state vehicle serves Oregon as well as Minnesota, requires vendors to work through three authorized wholesalers (AmerisourceBergen/Cencosa, Cardinal Health, and Morris & Dickson), and weights price competitiveness at 75 percent of evaluation criteria with contract term effective July 1, 2026.